Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Merck seeks to develop novel T-cell engager therapies with TriTAC platform, says GlobalData

Merck has recently agreed to acquire cancer drug developer Harpoon Therapeutics for about $680 million. The deal includes promising compounds undergoing Phase II trials for malignancies and access to the Tri-specific T cell Activating Construct (TriTAC) platform, positioning the US-based pharmaceutical giant for significant advancements in therapeutic innovation. The focus lies on contesting the evolving […]
Read more

BrainStorm Cell Therapeutics signals continued hope for NurOwn by securing patents, says GlobalData

BrainStorm Cell Therapeutics is still navigating a three-year regulatory journey for the NurOwn therapy that was initiated in February 2021, marked by the FDA’s initial discouragement of filing a Biologics License Application (BLA). However, the recent acquisition of three new patents for NurOwn and NurOwn-Exosomes remains a safeguard for NurOwn’s cell therapy, fostering hope for […]
Read more

Mazdutide positive phase III results to help Innovent gain widespread adoption in China obesity market, says GlobalData

Innovent Biologics has recently made a significant breakthrough in obesity treatment with mazdutide, showcasing promising Phase III (GLORY-1) results. Poised to enter the Chinese market, mazdutide heralds a new era in obesity management, reflecting the China-based biotech company’s commitment to innovative healthcare solutions and addressing the growing need for effective obesity treatments in one of […]
Read more

Drug price controls and emphasis on preventive care top solutions to address healthcare inflation, says GlobalData

Inflation in healthcare refers to the persistent increase in the cost of medical goods and services over time. This phenomenon is driven by a combination of factors, including advancements in medical technology, rising labor costs, pharmaceutical innovations, and the complex interplay of supply and demand within the healthcare market. While there are several options for […]
Read more

Despite argenx Vyvdura approval, quest for definitive myasthenia gravis cure persists in Japan, says GlobalData

Japan has recently approved argenx’s  Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous (SC) injection for the treatment of adult patients with generalized myasthenia gravis (gMG), who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). While introducing a novel subcutaneous administration route, Vyvdura adds to Japan’s myasthenia gravis (MG) treatment options. However, differentiation […]
Read more

Antibody drug conjugates focus draws global pharma giants attention to China, says GlobalData

Antibody-drug conjugates (ADCs) represent a significant breakthrough in targeted cancer therapy. By blending the specificity of monoclonal antibodies with the potency of cytotoxic drugs, ADCs offer a targeted approach to cancer treatment, minimizing the damage to healthy cells. China has become a major force in the advancement of this innovative field. Consequently, global pharma giants […]
Read more

Early diagnosis crucial for improving Gaucher disease patient outcomes, says GlobalData

Gaucher disease, a rare genetic disorder with significant health implications, has been at the forefront of recent medical discussions due to concerns over delayed diagnoses and treatment initiation. Despite advances in diagnostic methods, many patients still face extended periods before receiving an accurate diagnosis, impacting their treatment and overall health outcomes. The medical community, including […]
Read more

XORTX eyes CKD space with lead product XRX-008, says GlobalData

XORTX Therapeutics, a Canada-based late-stage clinical pharmaceutical company, has recently submitted a new patent for the treatment of chronic kidney disease (CKD). XORTX’s patent submission was supported by the efficacy and safety clinical data from a completed Phase II XRX-008 (oxypurinol) trial. If successful, it could be of high clinical value to physicians looking to […]
Read more

ADHD field presents significant opportunity for drug developers in 7MM, says GlobalData

Stimulants, amphetamines, and methylphenidates are the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the seven major markets (7MM*). Non-stimulants are mainly utilized as second-line therapies due to their lack of efficacy. However, stimulants are highly controlled substances, and prescriptions are often restricted to 30 days. This creates a demand for non-stimulants with […]
Read more

Obesity care needs greater revolution, says GlobalData

Novo Nordisk and Eli Lilly have been dominating the obesity scene in the past year with the approval of their glucagon-like peptide-1 receptor (GLP-1R) agonists Wegovy and Zepbound. Although medicines with other mechanisms of actions are available on the market, GLP-1R agonists seem to have a greater impact on weight loss and the patient’s life. […]
Read more

Zosurabalpin may end 50-year antibiotic discovery stalemate against Acinetobacter baumanni, says GlobalData

Zosurabalpin, a novel antibiotic currently in Phase I development by Roche, has recently showed promise in ending a 50-year drought in effective treatment against carbapenem-resistant Acinetobacter Baumanni (CRAB), which is categorized by the World Health Organisation (WHO) as a “priority 1 pathogen.” Demonstrating efficacy in vitro and in mouse models, zosurabalpin targets a critical bacterial […]
Read more

First-in-class Minerval shows promise in patients with advanced brain tumors, says GlobalData

Laminar Pharmaceuticals’ first-in-class autophagy inducer Minerval (LAM561, 2-hydroxyoleic acid (2-OHOA)) has reportedly demonstrated  encouraging activity in the difficult-to-treat malignant braintumor patient population, placing it as a potential candidate for the treatment of glioma and other solid tumor malignancies. With a unique membrane-level targeting approach and encouraging early-stage clinical trial data, Minerval holds potential to address […]
Read more
1 … 25 26 27 28 29 … 110